KEZAR LIFE SCIENCES INC (KZR)
US49372L1008 - Common Stock
KZR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. The financial health of KZR is average, but there are quite some concerns on its profitability. KZR does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
KZR had negative earnings in the past year.
In the past year KZR has reported a negative cash flow from operations.
In the past 5 years KZR always reported negative net income.
KZR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
KZR's Return On Assets of -62.08% is in line compared to the rest of the industry. KZR outperforms 40.18% of its industry peers.
KZR has a Return On Equity (-75.99%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.08% | ||
| ROE | -75.99% | ||
| ROIC | N/A |
ROA(3y)-31.3%
ROA(5y)-32.12%
ROE(3y)-35.78%
ROE(5y)-36.39%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KZR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KZR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KZR has been reduced compared to 1 year ago.
KZR has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, KZR has a worse debt to assets ratio.
2.2 Solvency
KZR has an Altman-Z score of -3.66. This is a bad value and indicates that KZR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.66, KZR is in line with its industry, outperforming 44.60% of the companies in the same industry.
A Debt/Equity ratio of 0.08 indicates that KZR is not too dependend on debt financing.
KZR's Debt to Equity ratio of 0.08 is on the low side compared to the rest of the industry. KZR is outperformed by 63.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.66 |
ROIC/WACCN/A
WACC12.67%
2.3 Liquidity
A Current Ratio of 7.65 indicates that KZR has no problem at all paying its short term obligations.
KZR has a better Current ratio (7.65) than 71.50% of its industry peers.
KZR has a Quick Ratio of 7.65. This indicates that KZR is financially healthy and has no problem in meeting its short term obligations.
KZR's Quick ratio of 7.65 is fine compared to the rest of the industry. KZR outperforms 71.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.65 |
3. Growth
3.1 Past
The earnings per share for KZR have decreased strongly by -631.15% in the last year.
EPS 1Y (TTM)-631.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-768.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
KZR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.02% yearly.
The Revenue is expected to grow by 2.75% on average over the next years.
EPS Next Y-509.06%
EPS Next 2Y-156.3%
EPS Next 3Y-75.43%
EPS Next 5Y-6.02%
Revenue Next Year-64.29%
Revenue Next 2Y-22.84%
Revenue Next 3Y-25.99%
Revenue Next 5Y2.75%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
KZR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KZR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
KZR's earnings are expected to decrease with -75.43% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-156.3%
EPS Next 3Y-75.43%
5. Dividend
5.1 Amount
No dividends for KZR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KEZAR LIFE SCIENCES INC
NASDAQ:KZR (12/20/2024, 8:21:39 PM)
After market: 6.36 -0.02 (-0.31%)6.38
-0.14 (-2.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners61.31%
Inst Owner Change-1.8%
Ins Owners2.59%
Ins Owner Change0%
Market Cap46.57M
Analysts74
Price Target14.79 (131.82%)
Short Float %N/A
Short Ratio0.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.59%
Min EPS beat(2)12.62%
Max EPS beat(2)16.56%
EPS beat(4)3
Avg EPS beat(4)6.31%
Min EPS beat(4)-14.7%
Max EPS beat(4)16.56%
EPS beat(8)5
Avg EPS beat(8)4.17%
EPS beat(12)9
Avg EPS beat(12)6.43%
EPS beat(16)11
Avg EPS beat(16)4.83%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)480%
PT rev (3m)97.73%
EPS NQ rev (1m)-765.77%
EPS NQ rev (3m)-765.77%
EPS NY rev (1m)30.68%
EPS NY rev (3m)-593.15%
Revenue NQ rev (1m)27.95%
Revenue NQ rev (3m)27.95%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.35 | ||
| P/tB | 0.35 | ||
| EV/EBITDA | N/A |
EPS(TTM)-8.92
EYN/A
EPS(NY)-9.26
Fwd EYN/A
FCF(TTM)-10.46
FCFYN/A
OCF(TTM)-10.46
OCFYN/A
SpS0.96
BVpS18.36
TBVpS18.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.08% | ||
| ROE | -75.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-31.3%
ROA(5y)-32.12%
ROE(3y)-35.78%
ROE(5y)-36.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.7% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.65 | ||
| Altman-Z | -3.66 |
F-Score3
WACC12.67%
ROIC/WACCN/A
Cap/Depr(3y)115.3%
Cap/Depr(5y)81.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-631.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-768.75%
EPS Next Y-509.06%
EPS Next 2Y-156.3%
EPS Next 3Y-75.43%
EPS Next 5Y-6.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-64.29%
Revenue Next 2Y-22.84%
Revenue Next 3Y-25.99%
Revenue Next 5Y2.75%
EBIT growth 1Y-47.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.31%
OCF growth 3YN/A
OCF growth 5YN/A